Y-Biologics (XKRX:338840) FCF Margin % : 0.00% (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Y-Biologics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Y-Biologics's Free Cash Flow for the three months ended in Mar. 2024 was ₩0 Mil. Y-Biologics's Revenue for the three months ended in Mar. 2024 was ₩1,143 Mil. Therefore, Y-Biologics's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.

As of today, Y-Biologics's current FCF Yield % is -6.12%.

The historical rank and industry rank for Y-Biologics's FCF Margin % or its related term are showing as below:

XKRX:338840' s FCF Margin % Range Over the Past 10 Years
Min: -1137.88 Med: -307.62 Max: -176.94
Current: -191.39

During the past 6 years, the highest FCF Margin % of Y-Biologics was -176.94%. The lowest was -1137.88%. And the median was -307.62%.

XKRX:338840's FCF Margin % is ranked worse than
53.82% of 1046 companies
in the Biotechnology industry
Industry Median: -144.01 vs XKRX:338840: -191.39

Y-Biologics FCF Margin % Historical Data

The historical data trend for Y-Biologics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Y-Biologics FCF Margin % Chart

Y-Biologics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

FCF Margin %

Get a 7-Day Free Trial

-546.01

-1,137.88

-176.94

-345.33

-269.90

Y-Biologics Quarterly Data
	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial				-167.35	-457.29	-98.23	-483.41	-

Competitive Comparison of Y-Biologics's FCF Margin %

For the Biotechnology subindustry, Y-Biologics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Y-Biologics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Y-Biologics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Y-Biologics's FCF Margin % falls into.

Y-Biologics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Y-Biologics's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-11202.233	/	4150.558
	=	-269.90 %

Y-Biologics's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	0	/	1142.665
	=	0.00 %

Y-Biologics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Y-Biologics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Y-Biologics (XKRX:338840) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Y-Biologics Inc (XKRX:338840) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 715, 17, Tech-ro 4-ro, Yuseong-gu, Daejeon, KOR

Website

https://www.ybiologics.com

Y-Biologics Inc is a company has a variety of development candidate antibodies based on Korea's highest-level antibody discovery platform technology and then independently develops antibody treatments or jointly develops cutting-edge biopharmaceuticals by fusing them with our partner's platform technology. Its main business model is based on a globally competitive antibody discovery platform and consists of development of new bio drug candidates and early technology transfer, and contract research services that generate stable cash flow.

Y-Biologics (XKRX:338840) Headlines

No Headlines